Martin et al, ABSTRACT 130

Dec 27, 2024

250 likes | 263 Views

This study by Martin et al. demonstrates the effectiveness of a multivalent adenovirus-based immunotherapy in inducing diverse, strong, and multifunctional T-cells in both naive and HBV-tolerant mice. The treatment shows promise for chronic hepatitis B management.

Share Presentation

Embed Code

dhaynes

Download Presentation

Martin et al, ABSTRACT 130

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Martin et al, ABSTRACT 130 A MULTIVALENT ADENOVIRUS-BASED IMMUNOTHERAPEUTIC FOR TREATMENT OF CHRONIC HEPATITIS B INDUCES BROAD, ROBUST AND POLYFUNCTIONAL T CELLS IN NAIVE AND HBV TOLERANT MICE

Bergh J et al. SABCS 2009;Abstract 23.

First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer . Bergh J et al. SABCS 2009;Abstract 23. Introduction.

275 views • 6 slides

Jones SE et al. SABCS 2009;Abstract 5082.

Cardiac Safety Results of a Phase II Trial of Adjuvant Docetaxel/Cyclophosphamide Plus Trastuzumab (Her TC) in HER2+ Early Stage Breast Cancer Patients. Jones SE et al. SABCS 2009;Abstract 5082. Introduction.

267 views • 9 slides

Perez EA et al. SABCS 2009;Abstract 80.

Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. Perez EA et al. SABCS 2009;Abstract 80. NCCTG N9831: Trial Schema. Accrual: 3,505 (Closed). Control Arm AC q3w x 4 → T qw x 12.

204 views • 6 slides

Grövdal M et al. Blood 2008;112:Abstract 223.

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy. Grövdal M et al. Blood 2008;112:Abstract 223. Introduction.

180 views • 5 slides

Rastelli A et al. SABCS 2009;Abstract 803.

A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast Cancer Patients with Marginal Vitamin D Status. Rastelli A et al. SABCS 2009;Abstract 803. Introduction.

162 views • 6 slides

Baselga J et al. SABCS 2009;Abstract 45.

SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer. Baselga J et al. SABCS 2009;Abstract 45. Introduction.

250 views • 6 slides

Erba HP et al. Blood 2008;112: Abstract 558

A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit: CLO24300606/CLASSIC II. Erba HP et al. Blood 2008;112: Abstract 558. Introduction.

195 views • 8 slides

Krop I et al. SABCS 2009;Abstract 5090.

A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug conjugate, in Patients with HER2+ Metastatic Breast Cancer who were Previously Treated with an Anthracycline, a Taxane, Capecitabine, Lapatinib and Trastuzumab. Krop I et al. SABCS 2009;Abstract 5090. Introduction.

224 views • 8 slides

1 Martin P et al. Proc ICML 2013;Abstract 063. 2 Morschhauser F et al.

424 views • 18 slides

Baum M et al. Proc ASCO 2010;Abstract LBA517. Vaidya JS et al.

Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority Phase 3 Trial. Baum M et al. Proc ASCO 2010;Abstract LBA517. Vaidya JS et al. Lancet 2010;[Epub ahead of print]. Introduction.

283 views • 9 slides

Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve-Month Efficacy and Safety from the Phase III DASISION Study. Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

331 views • 7 slides

Martin TG et al. Proc ASH 2013;Abstract 284.

SAR650984, a CD38 Monoclonal Antibody in Patients with Selected CD38+ Hematological Malignancies — Data from a Dose-Escalation Phase I Study. Martin TG et al. Proc ASH 2013;Abstract 284. Background.

293 views • 13 slides

Krag DN et al. Proc ASCO 2010;Abstract LBA505. Cote R et al. Proc ASCO 2010;Abstract CRA504.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer. Krag DN et al. Proc ASCO 2010;Abstract LBA505. Cote R et al. Proc ASCO 2010;Abstract CRA504. Giuliano AE et al. Proc ASCO 2010;Abstract CRA506. Overview.

430 views • 16 slides

Martin Diers, et al. 2010

Mirrored, imagined and executed movements differentially activated sensorimotor cortex in amputees with and without phantom limb pain. Martin Diers, et al. 2010. Phantom Limb Pain. Phantom Sensations Phantom Pain Can occur anywhere but most common in amputated limbs

510 views • 24 slides

Gradishar WJ et al. SABCS 2009;Abstract 44.

A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Gradishar WJ et al. SABCS 2009;Abstract 44. Introduction.

176 views • 8 slides

Miles DW et al. SABCS 2009;Abstract 41.

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). Miles DW et al.

253 views • 11 slides

Blackwell KL et al. SABCS 2009;Abstract 61

Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy. Blackwell KL et al. SABCS 2009;Abstract 61. Introduction.

233 views • 7 slides

More Related